검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Palifermin (Palifermin) Swedish Orphan Biovitrum·X-Linked Combined Immunodeficiency… 48 trials·t½ 4.5 h |
|---|---|
Overview Program | Palifermin |
Overview Company | Swedish Orphan Biovitrum |
Overview Modality | CGT |
Overview Target | X-Linked Combined Immunodeficiency Disea |
Overview Indication | X-linked Severe Combined Immunodeficiency (XSCID) |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarkers of radiation damage, and we validated radioprotection using WR-1065, the active form of Amifostine |
PK/PD Half-life | 4.5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III-IV trials.. Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and sa… |
Clinical PFS | 31 |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT01237951 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Palifermin (Palifermin) Swedish Orphan Biovitrum·X-Linked Combined Immunodeficiency… 48 trials·t½ 4.5 h |
|---|---|
Overview Program | Palifermin |
Overview Company | Swedish Orphan Biovitrum |
Overview Modality | CGT |
Overview Target | X-Linked Combined Immunodeficiency Disea |
Overview Indication | X-linked Severe Combined Immunodeficiency (XSCID) |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarkers of radiation damage, and we validated radioprotection using WR-1065, the active form of Amifostine |
PK/PD Half-life | 4.5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Clinical evidence for managing radiotherapy-induced oral mucositis and xerostomia in head and neck cancer patients: a review of Phase III-IV trials.. Oral Mucositis and xerostomia are common debilitating side effects of radiotherapy in head and neck cancer patients, leading to treatment interruptions and negatively impacting quality of life. This review was performed to examine the efficacy and sa… |
Clinical PFS | 31 |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT01237951 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교